Prediction: Novocure (NVCR) Will Beat the Market. Here's Why
Explore the exciting world of NovoCure (NASDAQ: NVCR) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!
*Stock prices used were the prices of Jan. 29, 2025. The video was published on March 4, 2025.
Don’t miss this second chance at a potentially lucrative opportunity
Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »
On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:
- Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $295,759!*
- Apple: if you invested $1,000 when we doubled down in 2008, you’d have $45,128!*
- Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $525,108!*
Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.
Continue »
*Stock Advisor returns as of March 3, 2025
Karl Thiel has positions in NovoCure. Keith Speights has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends NovoCure. The Motley Fool has a disclosure policy.
Recommended Articles
